He has more good days than bad days
In Göttingen, Germany, a team of researchers has taken a quiet but consequential step in the long human struggle against heart failure — a condition that has historically offered patients little more than management and waiting. By growing living cardiac tissue from a patient's own stem cells and suturing it directly onto the damaged heart, they have demonstrated, across four years of follow-up and twenty patients, that regeneration is not merely a hope but a measurable clinical reality. The findings, published in the New England Journal of Medicine, do not yet promise a cure for the millions affected worldwide, but they open a door that medicine has long sought: the possibility of restoring what was lost, rather than simply slowing its disappearance.
- Severe heart failure patients with hearts pumping at less than a third of normal capacity had exhausted every conventional option — medications, devices, transplant waiting lists — before this trial offered them something genuinely new.
- A bioengineered patch no larger than a postage stamp, grown from the patient's own stem cells and laced with collagen, was sutured onto the damaged heart and began contracting in rhythm with it — adding living muscle where scar tissue had silenced the organ.
- Twenty patients enrolled in a carefully staged trial beginning in 2021; imaging at three months confirmed thickening of the heart wall and improved pumping capacity, and crucially, those gains held across more than four years of follow-up.
- For patients like Steffen Eyring, whose heart had been pumping at just eighteen to twenty percent capacity after a 2020 heart attack, the result was not dramatic reversal but meaningful recovery — more good days, shorter walks that became possible again, a return to daily life.
- Researchers and clinicians are deliberate in their optimism: multi-center trials across Europe and the United States must follow before the patch becomes a standard treatment, but the medical community has received the results as a credible proof of concept for cardiac regeneration at scale.
In a hospital in Göttingen, Germany, a surgeon sutured a small patch of living tissue — grown in a laboratory from the patient's own stem cells — directly onto a failing heart. Once in place, it began to beat in rhythm with the damaged organ, adding functional muscle where scar tissue had taken over. The results of the trial that made this possible were published in the New England Journal of Medicine, and they represent something the field has long pursued: not mechanical assistance or organ replacement, but regeneration.
The twenty patients enrolled in the study shared a grim common ground. Their hearts pumped at less than thirty-five percent of normal capacity. They had already tried every available intervention — medications, implanted devices — and none had reversed the damage. A transplant meant an uncertain wait; a mechanical pump brought its own complications. The patch offered a third path.
The tissue itself is fabricated by extracting stem cells from a patient's blood, differentiating them into cardiac muscle and connective tissue cells, then combining them with collagen to form a thin, contractile sheet containing roughly eight hundred million cardiac cells. The biotechnology company Repairon GmbH handles manufacturing. The trial, which began in 2021, first confirmed a safe maximum dose, then treated sixteen patients with the full version. Imaging at three months showed measurable improvement in heart wall thickness and pumping capacity — and four years of follow-up confirmed those gains endured.
Among those patients was Steffen Eyring, fifty-eight, whose heart had been reduced to pumping at eighteen to twenty percent capacity after a 2020 heart attack. Despite medication and a defibrillator, he continued to decline. He and his wife Ina had tried to keep up their daily walks, but fatigue and breathlessness kept shortening the distance. After learning about the study from a television report, he volunteered. Surgery took place in June 2024. His function stabilized and improved slightly. "He has more good days than bad days," Ina said.
The researchers are measured in how they frame what comes next. Multi-center trials across Europe and the United States must follow before the patch can be offered as a standard treatment. But for the millions living with severe heart failure worldwide — and for the patients who have already received it — the patch represents something that did not previously exist: a clinical path toward repairing the heart rather than simply managing its decline.
In a hospital in Göttingen, Germany, a surgeon sutured a patch of living tissue directly onto a failing heart. The patch was no larger than a postage stamp, roughly three to four millimeters thick, and it had been grown in a laboratory from the patient's own stem cells. Once in place, it began to beat in rhythm with the damaged organ beneath it, adding muscle where scar tissue had taken over. This is not science fiction. It happened, and it worked.
The trial that made this possible enrolled twenty patients with severe heart failure—the kind that leaves conventional medicine with few options. These were people whose hearts pumped at less than thirty-five percent capacity, compared to the fifty-five to seventy percent of a healthy person. They had already tried the standard arsenal: medications, implanted devices, all the interventions that slow the disease but cannot repair it. For them, the only real alternatives were a heart transplant, which meant joining a long waiting list with no guarantee of a donor, or a mechanical pump, which came with its own set of complications and limitations. The patch offered something different: not replacement, not mechanical assistance, but regeneration.
The research was led by the University Medical Center Göttingen and the University Hospital of Schleswig-Holstein, with results published in the New England Journal of Medicine. The patch itself is made by extracting stem cells from a patient's blood, transforming them into cardiac muscle cells and connective tissue cells in the laboratory, then mixing them with collagen—the protein that gives human tissue its structure. The result is a thin sheet of living heart muscle that contracts on its own. The entire production process happens under controlled conditions, with the biotechnology company Repairon GmbH handling the manufacturing. Each patch can contain approximately eight hundred million cardiac cells.
The trial, which began in 2021, first established the safe maximum dose. Then, in the second phase, sixteen patients received the full dose. Three months after surgery, imaging showed the heart wall had thickened and pumping capacity had improved. The follow-up continued for more than four years, and the improvement held. Patients reported better quality of life. They could do things they had stopped being able to do.
One of those patients was Steffen Eyring, fifty-eight years old, who suffered a heart attack in 2020. His heart was so badly damaged that it pumped at only eighteen to twenty percent capacity. Despite medication and an implanted defibrillator, he kept getting worse. He and his wife, Ina, tried to maintain their daily walks, but exhaustion and breathlessness kept cutting the distance shorter. What took thirty minutes became forty, then longer still. He had to stop frequently to catch his breath. They learned about the study from a television report. Steffen volunteered. The surgery happened in June of 2024. Afterward, his heart function stabilized and improved slightly. "He can participate in daily life now," Ina said. "He has more good days than bad days."
Wolfram-Hubertus Zimmermann, the scientific director at Göttingen, framed the significance carefully: "For the first time in a larger clinical study, we have shown that it is possible to restore cardiac muscle function in people with advanced heart failure." Stephan Ensminger, the surgical director of the trial, added that they had "demonstrated that cardiac tissue cultivated from stem cells can be safely implanted in patients."
Heart failure affects roughly four million people in Germany alone and is one of the leading causes of death worldwide. It typically begins after a heart attack, when the muscle loses oxygen and cells die, leaving behind scar tissue that cannot contract or pump blood. The patch does not replace the heart or assist it mechanically. It adds new muscle that works alongside the existing tissue.
The researchers are careful about what comes next. The results have been well received in the medical community, but more work remains. Additional clinical trials will need to happen in hospitals across Europe and the United States, coordinated by the German Center for Cardiovascular Research and the University Medical Center Göttingen, before the patch can be offered widely as a standard treatment. For now, it remains a carefully controlled intervention for selected patients with severe disease. But for those patients, it represents something that did not exist before: a way to repair what was broken.
Notable Quotes
For the first time in a larger clinical study, we have shown that it is possible to restore cardiac muscle function in people with advanced heart failure.— Wolfram-Hubertus Zimmermann, scientific director at University Medical Center Göttingen
We have demonstrated that cardiac tissue cultivated from stem cells can be safely implanted in patients.— Stephan Ensminger, surgical director of the trial at University Hospital of Schleswig-Holstein
The Hearth Conversation Another angle on the story
What makes this different from a transplant, really? Both involve putting new tissue into the heart.
A transplant replaces the entire organ. This adds muscle to the damaged area. You keep your own heart; you're just giving it reinforcement. And you don't need to wait for a donor or take immunosuppressants for life.
How do they grow the tissue so quickly? The patient needs surgery within a reasonable timeframe.
They start with stem cells from the patient's own blood, which they already have. The laboratory can produce up to twenty patches under controlled conditions. The actual growth and differentiation happens in weeks, not months. It's still a process, but it's faster than waiting for a donor organ.
The trial was small—twenty patients. How confident should we be in these results?
Small, yes, but the follow-up was long. Four years of data showing the improvement held. That's significant. But you're right that larger trials are needed before this becomes routine. That's why they're planning multi-center studies across Europe and the US.
What about the patient you mentioned, Steffen? Is he cured?
Not cured. His heart function improved and stabilized. He went from barely being able to walk to having more good days than bad. That's not a cure in the traditional sense, but for someone with severe heart failure, it's a meaningful change in how he lives.
What's the biggest obstacle to making this widely available?
Scale and standardization. Right now it's being done at one hospital with one biotech company. You'd need to replicate that infrastructure in multiple centers, train surgeons, establish quality control. And you'd need to prove it works consistently across different populations and different hospitals. That takes time and money.